title: Novel graft copolymers enhance in vitro delivery of antisense oligonucleotides in the presence of serum.
abstract: Antisense technology holds tremendous potential in the research and clinical settings. However, successful delivery of antisense oligodeoxynucleotides (ODNs) to the intracellular site of action requires the passage of many barriers, including survival against extracellular serum nucleases and escape from endolysosomal degradation. Previous work has shown that the effectiveness of antisense delivery by the cationic liposome, dioleoyl-3-trimethylammonium-propane (DOTAP), is enhanced substantially by the incorporation of a pH-sensitive polymer, poly (propylacrylic acid) (PPAA), in serum-free media. To improve this system for application in serum-containing media conditions, PPAA was modified in this work by grafting onto it either poly(ethylene oxide) (PEO) or a more hydrophobic analog, poly (oxyalkylene amine), known as Jeffamine. The ternary formulation of DOTAP/ODN/PPAA-g-Jeffamine resulted in 8-fold increased uptake of fluorescently-labeled ODNs compared to DOTAP/ODN/PPAA and ~80% silencing of green fluorescent protein (GFP) expression in CHO-d1EGFP cells treated in the presence of 10% FBS-containing media. In contrast, the carrier systems that contained PPAA or PPAA-g-PEO failed to display any significant antisense activity in the presence of serum, even though all of the delivery systems displayed moderate to high levels of antisense activity in serum-free conditions. The results reveal that the carrier system with the Jeffamine graft copolymer effectively mediates specific gene silencing in the presence of serum, while the system with the PEO graft copolymer fails to do so. While the pH-dependent lytic functionality of PPAA was found to be lost upon grafting with PEO or Jeffamine, the hydrophobicity of the latter was sufficient to mediate cellular internalization and endosomal escape. Thus, the PPAA-g-Jeffamine copolymers hold substantial promise as agents for controlled therapeutic delivery of antisense oligonucleotides.
authors.affiliation: Department of Biomedical Engineering, Rutgers University, Piscataway, NJ 08854, USA.
authors.forename: Lavanya Y
authors.initials: LY
authors.lastname: Peddada
authors.forename: Nicole K
authors.initials: NK
authors.lastname: Harris
authors.forename: David I
authors.initials: DI
authors.lastname: Devore
authors.forename: Charles M
authors.initials: CM
authors.lastname: Roth
mesh_terms: D000179:Acrylates / Q000737:chemistry* / Q000633:toxicity; D000588:Amines / Q000737:chemistry*; D000818:Animals; D001692:Biological Transport; D016466:CHO Cells; D006224:Cricetinae; D003412:Cricetulus; D011992:Endosomes / Q000378:metabolism; D005229:Fatty Acids, Monounsaturated / Q000737:chemistry*; D020868:Gene Silencing; D017930:Genes, Reporter; D049452:Green Fluorescent Proteins / Q000096:biosynthesis / Q000235:genetics; D006461:Hemolysis / Q000187:drug effects; D006863:Hydrogen-Ion Concentration; D057927:Hydrophobic and Hydrophilic Interactions; D016376:Oligonucleotides, Antisense / Q000737:chemistry / Q000378:metabolism*; D011092:Polyethylene Glycols / Q000737:chemistry* / Q000633:toxicity; D011108:Polymers / Q000737:chemistry* / Q000633:toxicity; D000644:Quaternary Ammonium Compounds / Q000737:chemistry*; D044967:Serum / Q000378:metabolism*; D014162:Transfection
chemical_list: D000179:Acrylates; D000588:Amines; D005229:Fatty Acids, Monounsaturated; D016376:Oligonucleotides, Antisense; D011108:Polymers; D000644:Quaternary Ammonium Compounds; C485184:enhanced green fluorescent protein; C501628:poly(propyl acrylic acid); D049452:Green Fluorescent Proteins; D011092:Polyethylene Glycols; C070046:1,2-dioleoyloxy-3-(trimethylammonium)propane
references.citation: Gene Ther. 2000 Jan;7(2):126-38
references.pmid: 10673718
references.citation: J Control Release. 2004 Feb 10;94(2-3):447-51
references.pmid: 14976960
references.citation: Nat Biotechnol. 2007 May;25(5):497-9
references.pmid: 17483826
references.citation: Pharm Res. 2005 Jan;22(1):1-10
references.pmid: 15771224
references.citation: Nat Biotechnol. 2002 Feb;20(2):121-4
references.pmid: 11821852
references.citation: J Control Release. 2004 Jun 18;97(2):189-209
references.pmid: 15196747
references.citation: Pharmacol Rev. 2006 Mar;58(1):32-45
references.pmid: 16507881
references.citation: Adv Drug Deliv Rev. 2006 Jul 7;58(4):467-86
references.pmid: 16781003
references.citation: J Control Release. 2002 Jan 17;78(1-3):295-303
references.pmid: 11772470
references.citation: Annu Rev Biomed Eng. 2004;6:397-426
references.pmid: 15255775
references.citation: Nat Rev Drug Discov. 2002 Jul;1(7):503-14
references.pmid: 12120257
references.citation: Adv Genet. 2005;53:231-61
references.pmid: 16240996
references.citation: Nat Rev Cancer. 2005 Jun;5(6):468-79
references.pmid: 15905854
references.citation: Biomacromolecules. 2006 May;7(5):1502-8
references.pmid: 16677032
references.citation: Biomaterials. 2002 Jan;23(2):321-42
references.pmid: 11761152
references.citation: Proc Natl Acad Sci U S A. 1978 Jan;75(1):280-4
references.pmid: 75545
references.citation: Nucleic Acids Res. 2007;35(13):4396-408
references.pmid: 17576672
references.citation: J Control Release. 2005 Jan 3;101(1-3):259-71
references.pmid: 15588910
references.citation: J Control Release. 1999 Aug 27;61(1-2):137-43
references.pmid: 10469910
references.citation: Expert Opin Drug Deliv. 2008 Jan;5(1):25-44
references.pmid: 18095927
references.citation: Adv Genet. 2005;53PA:231-261
references.pmid: 16243066
references.citation: J Pharm Pharmacol. 2003 Apr;55(4):453-60
references.pmid: 12803766
references.citation: Eur J Pharm Biopharm. 2003 Sep;56(2):237-46
references.pmid: 12957638
references.citation: Adv Drug Deliv Rev. 2005 Dec 14;57(15):2215-37
references.pmid: 16297497
references.citation: Bioconjug Chem. 2008 May;19(5):1040-8
references.pmid: 18419148
references.citation: Bioconjug Chem. 2001 Nov-Dec;12(6):906-10
references.pmid: 11716680